MAXX-CALZIUM Trademark

Trademark Overview


On Wednesday, August 14, 2019, a trademark application was filed for MAXX-CALZIUM with the United States Patent and Trademark Office. The USPTO has given the MAXX-CALZIUM trademark a serial number of 79269290. The federal status of this trademark filing is REGISTERED as of Tuesday, September 29, 2020. This trademark is owned by Zobrius Pharma AS. The MAXX-CALZIUM trademark is filed in the Pharmaceutical Products category with the following description:

Dietary supplements made in whole or in significant part of calcium
maxx-calzium

General Information


Serial Number79269290
Word MarkMAXX-CALZIUM
Filing DateWednesday, August 14, 2019
Status700 - REGISTERED
Status DateTuesday, September 29, 2020
Registration Number6160698
Registration DateTuesday, September 29, 2020
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 14, 2020

Trademark Statements


Description of MarkThe mark consists of the wording "MAXX-CALZIUM" in stylized gold font below a grouping of plural, gold, rounded shapes of varying ellipticity, which shapes generally increase in size from left to right, and the grouping forms the combined shape of a stylized egg. Below the stylized egg is an elliptical gold shadow effect.
Goods and ServicesDietary supplements made in whole or in significant part of calcium
Pseudo MarkMAX-CALCIUM
Indication of Colors claimedThe color(s) gold is/are claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 16, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameZobrius Pharma AS
Party Type30 - Original Registrant
Legal Entity Type24 - NOT AVAILABLE
AddressNO

Party NameZobrius Pharma AS
Party Type20 - Owner at Publication
Legal Entity Type24 - NOT AVAILABLE
AddressNO

Party NameZobrius Pharma AS
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressNO

Trademark Events


Event DateEvent Description
Tuesday, October 22, 2019APPLICATION FILING RECEIPT MAILED
Wednesday, November 13, 2019NON-FINAL ACTION WRITTEN
Thursday, December 5, 2019REFUSAL PROCESSED BY MPU
Thursday, October 10, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, October 16, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 13, 2019ASSIGNED TO EXAMINER
Thursday, November 14, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, December 5, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, December 20, 2019REFUSAL PROCESSED BY IB
Tuesday, June 2, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 2, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 2, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 8, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 24, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 14, 2020PUBLISHED FOR OPPOSITION
Tuesday, July 14, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, August 13, 2020NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, December 29, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, January 13, 2021FINAL DISPOSITION NOTICE SENT TO IB
Saturday, January 30, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, September 29, 2025COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, July 3, 2025NEW REPRESENTATIVE AT IB RECEIVED
Thursday, May 28, 2020NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, September 29, 2020REGISTERED-PRINCIPAL REGISTER
Wednesday, January 13, 2021FINAL DISPOSITION PROCESSED
Tuesday, May 18, 2021NEW REPRESENTATIVE AT IB RECEIVED
Sunday, September 18, 2022NEW REPRESENTATIVE AT IB RECEIVED